John Youshia

Dr. John Youshia

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
John YoushiaJohn Youshia
John Youshia
MAMohamed Ehab Ali
Mohamed Ehab Ali
Alf LamprechtAlf Lamprecht
Alf Lamprecht

4 December 2015 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
John YoushiaJohn Youshia
John Youshia
Alf LamprechtAlf Lamprecht
Alf Lamprecht
Introduction: Inflammatory bowel disease (IBD) is a chronic autoimmune disease, whose main forms are Crohn’s disease and ulcerative colitis. The main treatment of IBD includes oral administration o...

1 August 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
John YoushiaJohn Youshia
John Youshia
AKAmany O. Kamel
Amany O. Kamel
ASAbdelhameed El Shamy
Abdelhameed El Shamy
SMSamar Mansour
Samar Mansour

27 June 2023 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
DHDiana M.F. Hanna
Diana M.F. Hanna
John YoushiaJohn Youshia
John Youshia
SFSarah Farid Fahmy
Sarah Farid Fahmy
MGMina Y. George
Mina Y. George
Oxaliplatininduces chemobrain in cancer patients/survivors. Nutraceuticalnaringin has antioxidant and anti-inflammatory properties with low oralbioavailability. Our aim was to formulate naringin in chitosan nanoparticles fornose to brain delivery and assess its neuroprotective effect against oxaliplatin-inducedchemobrain in rats. Naringinchitosan nanoparticles were prepared by ionic gelation. Rats were administeredoral naringin (80 mg/kg), intranasal naringin (0.3 mg/kg) or intranasal naringin-loadedchitosan nanoparticles (0.3 mg/kg). Naringin's neuroprotective efficacy wasassessed based on behavioral tests, histopathology, and measuring oxidativestress and inflammatory markers. Selectednanoparticles formulation showed drug loading of 5%, size of 150 nm and werecationic. Intranasal naringin administration enhanced memory function,inhibited hippocampal acetylcholinesterase activity, and corrected oxaliplatin-inducedhistological changes. Moreover, it reduced malondialdehyde and elevated reducedglutathione hippocampal levels. Furthermore, it decreased levels of inflammatorymarkers: NF-kB and TNF-α by 1.25-fold.Upstream to this inflammatory status, intranasal naringin downregulated thehippocampal protein levels of two pathways: cGAS/STINGand HMGB1/RAGE/TLR2/MYD88. Intranasalnaringin-loaded chitosan nanoparticles showed superior amelioration ofoxaliplatin-induced chemobrain in rats at a dose 267-fold lower to thatadministered orally. The potential involvement of cGAS/STINGand HMGB1/RAGE/TLR2/MYD88 pathways in the mechanistic process of eitheroxaliplatin-induced chemobrain or naringin-mediated neuroprotection was evidenced.

1 March 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SESara El-Safy
Sara El-Safy
STSalma N. Tammam
Salma N. Tammam
Mohammad Abdel-HalimMohammad Abdel-Halim
Mohammad Abdel-Halim
MAMohamed E. Ali
Mohamed E. Ali
John YoushiaJohn Youshia
John Youshia
SMSamar Mansour
Samar Mansour

1 May 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
AKAmany Kamel
Amany Kamel
John YoushiaJohn Youshia
John Youshia
ESEl Shamy
El Shamy
SMSamar Mansour
Samar Mansour
Peer reviewed article authored by (Youshia J, Kamel AO, El Shamy A, Mansour S). Read article or submit your manuscript for publishing.